DISCO Pharmaceuticals
Germany
activeseed
seed
Stage
3
Investors
About
DISCO Pharmaceuticals employs a disruptive proteomics technology to map the surfaceome of cancer cells and develop first-in-class cancer drugs by identifying druggable targets and protein communities on the cancer cell surface.
Explore DISCO Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.